Biological Factors
Resolution Therapeutics Secures £63.5M in Series B Funding to Advance Macrophage Cell Therapy for Liver Disease
Resolution Therapeutics, Series B funding, macrophage cell therapy, liver disease, regenerative medicine, biopharmaceuticals
Johnson & Johnson Invests $2 Billion in New North Carolina Biologics Facility
Johnson & Johnson, North Carolina, Biologics Facility, Pharmaceutical Manufacturing, Investment
Eli Lilly Expands Irish Manufacturing with Additional $1B Investment
Eli Lilly, Ireland, manufacturing expansion, biologics, pharmaceuticals, investment, Limerick, Kinsale
Innovent Biologics Reports Promising Results in Early-Stage Study of Bispecific Antibody IBI363 in Lung Cancer Patients
Innovent Biologics, IBI363, Bispecific Antibody, Lung Cancer, Early-Stage Study, PD-1/IL-2 α-bias, Non-Small Cell Lung Cancer (NSCLC)
Key Democrat to Oppose Biosecure Act, Citing Concerns Over Legislation’s Design and Impact on U.S.-China Biotech Relations
Biosecure Act, U.S.-China relations, biotech restrictions, national security, WuXi Biologics, BGI, Congressional opposition
AstraZeneca Invests $135M in Swedish Biologics Manufacturing Expansion
AstraZeneca, biologics manufacturing, Sweden, expansion, investment
WuXi Biologics’ ADC Spinout Sees Revenue Surge Amid Biosecure Threat
WuXi Biologics, ADC spinout, revenue jump, Biosecure risk, CRDMO, bioconjugate market
Aeterna Zentaris Rebrands as COSCIENS Biopharma: A New Era in Biopharmaceuticals
Aeterna Zentaris, COSCIENS Biopharma, biopharmaceuticals, rebranding, name change, therapeutic development, diagnostic tests, Macrilen, adult growth hormone deficiency
venBio Secures $528M for Fifth Life Sciences Venture Capital Fund
venBio, life sciences, venture capital, fund closing, biotech startups, biopharmaceuticals
BeiGene CEO Eyes Biologics Deals for New US Innovation Center in New Jersey
BeiGene, biologics, innovation center, New Jersey, deals, CEO, John Oyler